BioTherapeutics, Inc. (BTI) is at the forefront of precision medicine, focusing on innovative approaches to prevent and treat inflammation and metabolic diseases. One of their key technologies involves the use of abscisic acid (ABA), derived from fig extract, which has shown promise in improving glucose tolerance and insulin sensitivity, particularly in pre-diabetic patients. BTI is also developing ABA as a nutraceutical aimed at glycemic control, highlighting its potential role in managing diabetes. Their research includes advanced computational methods to model the interactions between diet, microbiome, metabolism, and immunity, which are crucial for understanding and developing effective treatments for autoimmune and metabolic disorders.

In addition to their work with ABA, BTI employs a sophisticated informatics platform known as intelligent Medicine (iMED), which integrates various modeling techniques and artificial intelligence to analyze complex biological systems. This platform enables the creation of synthetic patient cohorts for in silico clinical trials, allowing for personalized medicine strategies tailored to individual patient needs. By leveraging large-scale electronic health records and advanced machine learning algorithms, BTI aims to uncover insights that can lead to safer and more effective treatments. Their commitment to a holistic approach in drug discovery and development positions them as a leader in the evolving landscape of precision medicine.

United States

BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health.

Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.

BioTherapeutics

Company Details